Pharma BD Deal Intelligence

Proliant Health and Biologicals / Dyadic International, Inc.

2024 · Licensing/Option · Complete

Dyadic International and Proliant Health and Biologicals announced a development and commercialization partnership under which Proliant will use Dyadic's C1 and Dapibus filamentous fungal expression platforms to produce and commercialize animal-free recombinant human serum albumin. Dyadic receives a USD 1.5 million upfront milestone payment plus profit sharing on product sales, with first product launch anticipated in the first half of 2025.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2029 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2024 deals